2 min read
Regeneron’s Evicanumab Fights Ultra-Rare Form of High Cholesterol in Kids
Regeneron’s Evicanumab Fights Ultra-Rare Form of High Cholesterol in Kids Published: May 23, 2022 By Vanessa Doctor, RN BioSpace Regeneron
Tag : Monoclonal Antibodies
2 min read
2 min read
Regeneron’s Evicanumab Fights Ultra-Rare Form of High Cholesterol in Kids
Regeneron’s Evicanumab Fights Ultra-Rare Form of High Cholesterol in Kids Published: May 23, 2022 By Vanessa Doctor, RN BioSpace Regeneron
2 min read
UCB psoriasis drug will need to wait for US approval
UCB psoriasis drug will need to wait for US approval Published: May 13, 2022 By Mark Terry BioSpace It won’t be a happy weekend for UCB as the
3 min read
Regeneron Overcomes Loss of COVID Antibody to Post Positive First Quarter
Regeneron Overcomes Loss of COVID Antibody to Post Positive First Quarter Published: May 04, 2022 By Alex Keown BioSpace Despite the loss of
2 min read
AstraZeneca Touts Evusheld’s Efficacy in High-Risk Patients
AstraZeneca Touts Evusheld’s Efficacy in High-Risk Patients Published: Apr 21, 2022 By Jazmine Colatriano, M.S. BioSpace Clinical results
3 min read
Sean Hannity: Horse Paster? I Don't Even Know Her!
Fox News host Sean Hannity, never one to let a good fabrication get in the way of reality, lied his fool face off Friday and insisted that he had
15 min read
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related
3 min read
Senate Agrees To $10 Billion In Extra COVID $$$, After GOP A Bunch Of Dicks About It
The US Senate agreed yesterday on a $10 billion plan to fund coronavirus treatments, vaccinations, and vaccine research, heading off the possibility
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
April 01, 2022 09:00 ET | Source: Y-mAbs Therapeutics, Inc NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the
1 min read
U.S. will run out of key COVID treatments without more funds, White House says
U.S. will run out of key COVID treatments without more funds, White House says March 15, 2022; 11:54 AM EDT By Jeff Mason WASHINGTON, March 15
4 min read
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19 February 25, 2022 06:00 ET
3 min read
COVID-19 Update: Omicron BA.2 Raises Questions, FDA Limits GSK Antibody
COVID-19 Update: Omicron BA.2 Raises Questions, FDA Limits GSK Antibody Published: Feb 24, 2022 By Mark Terry BioSpace The new normal may not be
1 min read
U.S. FDA limits use of GlaxoSmithKline-Vir COVID-19 drug
U.S. FDA limits use of GlaxoSmithKline-Vir COVID-19 drug February 23, 2022; 2:45 PM EST (Reuters) – The U.S. Food and Drug Administration said on
Pandemic leads to broader use of monoclonal antibodies
by Bill Snyder New cases of COVID-19 in the United States have dropped by about 75% from the latest peak in mid-January, but as of Feb. 14, the
1 min read
GSK-Vir therapy has neutralizing activity against Omicron sub-variant, data shows
GSK-Vir therapy has neutralizing activity against Omicron sub-variant, data shows February 10, 2022; 3:51 AM EST (Updated 3:04 PM EST) (Reuters) –